Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company whose news flow is driven by developments in its allogeneic CAR-T cell therapy programs and related corporate updates. The company focuses on vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma.
News about Caribou frequently covers clinical trial milestones, including data readouts from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. Company press releases have highlighted efficacy and durability data in defined patient cohorts, safety profiles that support outpatient administration for vispa-cel, and dose selection and expansion plans for CB-011 in heavily pretreated multiple myeloma populations.
Investors and followers of CRBU can also expect updates on regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug status, as well as communications about planned pivotal trial designs. In addition, Caribou issues quarterly financial results and business updates via press releases and Form 8-K filings, which provide context on its operating runway, research and development spending, and strategic pipeline prioritization.
Another recurring category of news involves conference participation and webcasts, where Caribou’s management and clinical investigators present data at major hematology and oncology meetings and biopharma investor conferences. These events often coincide with new clinical data disclosures or discussions of next steps in trial development.
This news page aggregates such announcements so readers can follow Caribou’s progress in CRISPR-based genome editing, allogeneic CAR-T development, and its lead programs in lymphoma and multiple myeloma. For those tracking CRBU, regular review of this feed helps monitor key clinical, regulatory, and corporate milestones.
Caribou Biosciences (Nasdaq: CRBU) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. Key financials: FY2025 licensing revenue $11.2M, GAAP net loss $148.1M ($1.59/sh), non-recurring impairment $21.3M and $142.8M cash at year-end. Management expects cash to fund operations into 2H 2027 while exploring options to fully fund a vispa-cel pivotal trial.
Clinical: vispa-cel showed efficacy and durability in 2L LBCL comparable to autologous CAR-T; Caribou is engaging the FDA on pivotal design. CB-011 dose expansion for r/r multiple myeloma initiated with planned data updates in 2026.
Caribou Biosciences (Nasdaq: CRBU) said management will attend two investor conferences in February–March 2026. Key engagements include a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Feb 19, 2026 at 10:45 AM ET and a fireside chat at the Leerink Global Healthcare Conference in Miami on Mar 10, 2026 at 8:00 AM ET.
A webcast of the Leerink presentation will be available via the company Events page and accessible for at least 30 days after the event.
Caribou Biosciences (Nasdaq: CRBU) announced late-breaking presentations at the 2026 Tandem Meetings (Feb 4-7, Salt Lake City) featuring updated clinical and new translational data for two allogeneic CAR-T programs.
Vispa-cel (CB-010) ANTLER poster (Feb 5) reports efficacy and durability reportedly on par with autologous CAR-T in second-line large B cell lymphoma. CB-011 CaMMouflage oral (Feb 7) shows CAR-T expansion correlating with deep, durable responses and supports the selected regimen for dose expansion. Abstracts are available at tandemmeetings.com and presentations will be posted on Caribou’s Scientific Publications page after the event.
Caribou Biosciences (Nasdaq: CRBU) will host an in-person and virtual KOL panel at the 67th ASH Annual Meeting on Dec 6, 2025 at 7:30 AM ET to discuss vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy. The session will examine how vispa-cel may broaden access to second-line large B cell lymphoma care by enabling CAR-T delivery in community hospitals and academic centers.
The event is moderated by Tina Albertson, MD, PhD, and features clinicians from Utah Cancer Specialists, Bozeman Health, Medical College of Wisconsin, and University of Kansas Cancer Center. In-person attendance is invite-only; a webcast and replay will be available and registration is on the company Events page.
Caribou Biosciences (Nasdaq: CRBU) reported Q3 2025 results and clinical updates on Nov 12, 2025. Key clinical data show vispa-cel (CB-010) ANTLER phase 1 confirmatory cohort (N=22) achieved 82% ORR, 64% CR, and 51% 12‑month PFS (data cutoff Sep 29, 2025). An optimized vispa-cel profile (N=35) showed 86% ORR, 63% CR, and 53% 12‑month PFS (median follow‑up 11.8 months).
CB-011 (CaMMouflage phase 1) dose‑escalation RDE 450M cells; BCMA‑naïve RDE cohort (12 pts, cutoff Sep 24, 2025) showed 92% ORR, 75% ≥CR, and 91% MRD‑negativity (10/11 evaluable). Company had $159.2M cash and expects funding into 2H 2027 while exploring options to fully fund pivotal vispa-cel trial.
Caribou Biosciences (Nasdaq: CRBU) said company management will participate in investor conferences in November and December 2025.
Scheduled appearances: 2025 Truist Securities BioPharma Symposium, New York — November 6, 2025, and 8th Annual Evercore Healthcare Conference, Coral Gables, FL — December 2, 2025 with a fireside chat at 8:45–9:05 AM ET. Webcasts and event links will be posted on the company Events page and will be available for at least 30 days after each event.
Caribou Biosciences (Nasdaq: CRBU) reported positive ANTLER Phase 1 data for allogeneic CAR-T therapy vispa-cel (CB-010) with confirmatory cohort (N=22) showing 82% ORR, 64% CR and 51% 12‑month PFS (efficacy cutoff Sep 29, 2025). An optimized-profile cohort (N=35) showed 86% ORR, 63% CR and 53% 12‑month PFS with median follow-up 11.8 months. Safety (safety cutoff Sep 2, 2025) across N=84 shows manageable events: thrombocytopenia 62%, CRS 55% (grade ≥3 <5%), no GvHD and no ≥grade 3 ICANS in key cohorts. Company plans a randomized pivotal Phase 3 (~250 patients) in 2L LBCL per FDA recommendation and held a webcast on Nov 3, 2025.
Caribou Biosciences (Nasdaq: CRBU) reported first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The 450x10^6 CAR-T cell dose is the recommended dose for expansion (RDE); dose expansion is planned to start by year-end with data expected in 2026. In 12 BCMA-naïve patients at the RDE (median follow-up 8.3 months) the trial showed 92% ORR, 75% ≥CR, and 91% MRD negativity (≤10^-5). Safety was described as manageable but included cytopenias, infections and isolated serious adverse events.
Caribou Biosciences (Nasdaq: CRBU) will host a live webcast at 8:00 am ET on Monday, November 3, 2025 to report new clinical data.
The presentation will cover updated results from the ANTLER Phase 1 trial of vispacabtagene regedleucel (vispa-cel; formerly CB-010) in relapsed or refractory B cell non-Hodgkin lymphoma and the first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The company will also outline its anticipated pivotal Phase 3 trial design for vispa-cel and next steps for CB-011 development.
A live webcast is available on Caribou’s Events page and the archived webcast will be accessible for 30 days after the event.
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in the upcoming Citi 2025 Biopharma Back to School Conference. Rachel Haurwitz, PhD, the company's president and CEO, will engage in a fireside chat on September 3, 2025 at 2:30 PM EDT.
The presentation will be accessible through a webcast on Caribou's website's Events page and will remain available for at least 30 days following the event.